These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dynamical properties and tumor clearance conditions for a nine-dimensional model of bladder cancer immunotherapy. Starkov KE; Bunimovich-Mendrazitsky S Math Biosci Eng; 2016 Oct; 13(5):1059-1075. PubMed ID: 27775397 [TBL] [Abstract][Full Text] [Related]
5. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Zuiverloon TC; Nieuweboer AJ; Vékony H; Kirkels WJ; Bangma CH; Zwarthoff EC Eur Urol; 2012 Jan; 61(1):128-45. PubMed ID: 22000498 [TBL] [Abstract][Full Text] [Related]
6. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors. Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563 [TBL] [Abstract][Full Text] [Related]
7. BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model. Rentsch CA; Biot C; Gsponer JR; Bachmann A; Albert ML; Breban R PLoS One; 2013; 8(2):e56327. PubMed ID: 23451041 [TBL] [Abstract][Full Text] [Related]
9. Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guérin immunotherapy. Jackson AM; Alexandrov AB; Prescott S; James K Cancer Immunol Immunother; 1995 Feb; 40(2):119-24. PubMed ID: 7882382 [TBL] [Abstract][Full Text] [Related]
10. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941 [TBL] [Abstract][Full Text] [Related]
11. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Watanabe E; Matsuyama H; Matsuda K; Ohmi C; Tei Y; Yoshihiro S; Ohmoto Y; Naito K Cancer Immunol Immunother; 2003 Aug; 52(8):481-6. PubMed ID: 12707736 [TBL] [Abstract][Full Text] [Related]
12. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Saint F; Kurth N; Maille P; Vordos D; Hoznek A; Soyeux P; Patard JJ; Abbou CC; Chopin DK Int J Cancer; 2003 Nov; 107(3):434-40. PubMed ID: 14506744 [TBL] [Abstract][Full Text] [Related]
13. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Kamat AM; Flaig TW; Grossman HB; Konety B; Lamm D; O'Donnell MA; Uchio E; Efstathiou JA; Taylor JA Nat Rev Urol; 2015 Apr; 12(4):225-35. PubMed ID: 25800393 [TBL] [Abstract][Full Text] [Related]
14. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842 [TBL] [Abstract][Full Text] [Related]
15. BCG and IL - 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method-stability analysis. Nave O; Hareli S; Elbaz M; Iluz IH; Bunimovich-Mendrazitsky S Math Biosci Eng; 2019 Jun; 16(5):5346-5379. PubMed ID: 31499716 [TBL] [Abstract][Full Text] [Related]
16. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Decobert M; LaRue H; Harel F; Meyer F; Fradet Y; Lacombe L Cancer; 2008 Aug; 113(4):710-6. PubMed ID: 18543328 [TBL] [Abstract][Full Text] [Related]